ClinicalTrials.gg
RecruitingNCT06239194Updated Oct 15, 2026

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of MDX2001 in Biliary Tract Cancer, Breast Cancer and Cervical Cancer, sponsored by ModeX Therapeutics, An OPKO Health Company. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionGallbladder NeoplasmsRegistry: Biliary Tract NeoplasmsReclassifiedWhy we changed it
Registry
Biliary Tract Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gallbladder Neoplasms
Why
  1. The study's listed conditions name Gallbladder Neoplasms, a narrower term within Biliary Tract Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModeX Therapeutics, An OPKO Health Company (part of OPKO Health, Inc.) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 15, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 147 studies in Gallbladder Neoplasms with a site in United States — 16 open to participants now, 27 under way, 6 of them phase 3. Gallbladder Neoplasms · United States.

Planned enrollment
10th of 127
330 · median 44
Started
2024
with 2 others
Phase 1/2
11 of 147
3 open now
Primary completion
2028-08
later than 17 of 26 live
Registered
136th of 147
by date

Among the 147 studies in Gallbladder Neoplasms with a site in United States, this one is the 10th largest by planned enrollment of the 127 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 1/2, reaches primary completion later than 17 of the 26 other live ones, and was the 136th registered.

Gallbladder Neoplasms

301 studies on the registry are indexed under Gallbladder Neoplasms; 65 are open to participants now.

Browse Gallbladder Neoplasms studies →

Open to participants now

16 of the 147 studies in Gallbladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Gallbladder Neoplasms studies recruiting now, 24 (56%) set no upper age limit and 8 (19%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Gallbladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Read the detailed description

This study consists of Phase 1a dose escalation, Phase 1b dose expansion in a single indication, and Phase 2a expansion in a single indication.

Primary Objectives

  • All Phases: Evaluate the safety and tolerability of MDX2001 in patients with advanced solid tumor malignancies
  • Phase 1 only: Identify a recommended Phase 2 dose (RP2D) for further development of MDX2001
  • For Phase 1b and Phase 2: Assess the anti-tumor efficacy of MDX2001 in patients with selected advanced solid tumor malignancies

Secondary Objectives:

  • Further characterize the anti-tumor activity of MDX2001 based on additional assessments of clinical benefit
  • Characterize the pharmacokinetics of MDX2001
  • Characterize the immunogenicity of MDX2001
  • Characterize relationship of baseline target protein expression in tumor tissue and clinical benefit

The expected duration of study intervention for patients may vary, based on progression date. The median expected duration of study per patient is estimated to be 10 months (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up).

03

Conditions studied

  • Biliary Tract Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Head and Neck Cancer
  • Hepatocellular Cancer
  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Renal Cancer
  • Thyroid Cancer
  • Urothelial Carcinoma (UC)
  • Cholangiocarcinoma
  • Mesothelioma
  • Gallbladder Cancer
  • Ovarian Cancer
04

In context

Gallbladder Neoplasms Reclassified

301 studies on the registry are indexed under Gallbladder Neoplasms; 65 are open to participants now.

This study's planned enrollment of 330 is above the median of 56 across 222 interventional studies indexed under Gallbladder Neoplasms.

Browse Gallbladder Neoplasms studies →

Lead sponsor

ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

First submitted after ModeX Therapeutics became part of OPKO Health, Inc..

Compared within Gallbladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Biliary Tract Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age
  • or cytologically confirmed diagnosis of solid tumors
  • (ECOG) performance status 0-1
  • All patients should have at least 1 per v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
  • All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Adequate hematologic, hepatic and renal function
  • Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • Any cardiac disease
  • Unresolved toxicities from previous anticancer therapy
  • Prior solid organ or hematologic transplant
  • Known untreated, active, or uncontrolled
  • Known positivity with (HIV), known active or C, or uncontrolled chronic or ongoing infectiion requiring intravenous treatment.
  • Receipt of a live-virus vaccination within 28 days of planned treatment start
  • Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.
  • Participation in a concurrent clinical study in the treatment period.
  • Known to MDX2001 or any of its ingredients
  • Supplemental oxygen use for activities of daily living

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Phase 1a - MDX2001 Dose Escalation

    Patients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection.

    Drug: MDX2001

  • Experimental
    Phase 1b - Indication Optimization

    Patients with a single tumor indication receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection.

    Drug: MDX2001

  • Experimental
    Phase 1b - Dose Optimization

    Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection.

    Drug: MDX2001

  • Experimental
    Phase 2a - Cohort Expansion

    Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection at the recommended Phase 2 dose.

    Drug: MDX2001

Interventions

  • DrugMDX2001

    MDX2001 intravenous infusion or subcutaneous (SC) injection.

07

What researchers measure

Primary outcomes

  1. All Phases: Adverse events (AEs)

    Incidence and severity of AEs and serious AEs (SAEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 including changes in clinical laboratory parameters

    Time frame: Baseline until end of study, up to approximately 9 months

  2. Phase 1b and Phase 2a: Objective response rate of MDX2001

    Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  3. Phase 1: Recommended Phase 2 dose (RP2D)

    Recommended Phase 2 dose is determined following the evaluation of MDX2001 safety including the incidences of dose limiting toxicities (DLTs), MDX2001 anti-tumor activity, and MDX2001 pharmacokinetics

    Time frame: Baseline until end of study, up to approximately 9 months

Secondary outcomes

  1. Phase 1a: Objective response rate of MDX2001

    Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  2. All Phases: Duration of response (DOR)

    Duration of response is defined as the time from first documentation of response (complete response \[CR\] or partial response \[PR\]) to documentation of objective disease progression or death due to any cause, whichever occurs first

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  3. All Phases: Time to response (TTR)

    Time to response is defined as the time from first dose to first documentation of response (CR or PR)

    Time frame: From date of enrollment until the first documentation of response (CR or PR), approximately 4 months

  4. All Phases: Disease control rate (DCR)

    Disease control rate is defined as the proportion of evaluable patients with a best overall response (BOR) of stable disease, CR or PR

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  5. All Phases: Progression free survival (PFS)

    Progression-free survival is defined as the time from the first dose to the date of disease progression or death (any cause), whichever occurs first

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

  6. All Phases: Pharmacokinetic Parameter Cmax of MDX2001

    Maximum observed plasma concentration

    Time frame: From date of enrollment until completion of the 6th cycle of treatment, up to approximately 6 months

  7. All Phases: Pharmacokinetic parameter area under the curve (AUC(0-T)) of MDX2001

    Area under the plasma concentration versus time curve

    Time frame: From date of enrollment until the completion of the 3rd cycle of treatment, up to approximately 3 months

  8. All Phases: Evaluation of MDX2001 immunogenicity

    The presence and persistence of anti-MDX2001 antibodies

    Time frame: Baseline until end of study, up to approximately 9 months

  9. All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001

    Relationship between H score cell surface target protein expression in tumor tissue at baseline and objective responses with MDX2001

    Time frame: Baseline until the end of treatment, up to approximately 6 months

08

Study locations

6 of 6 sites recruiting
09

References and documents

Publications

  • Dumbrava E, Minchom A, Henry J, Johnson M, Sommerhalder D, Merchan J, Heist R, Cabanas EG, Cotreau M, Goenaga AL, Burzyn D, Makris L, Culm K, Abbadessa G. MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. Future Oncol. 2026 Feb;22(3):305-312. doi: 10.1080/14796694.2025.2610468. Epub 2026 Jan 6. PubMed 41495607 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Aug 2028, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Feb 2, 2024
StartActual
Jun 12, 2024
Primary completionEst.
Aug 2028
CompletionEst.
Feb 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
285→330
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Massachusetts General Hospital · Boston, United StatesContact person changed (no phone or email listed)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Enrollment 285→330
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Massachusetts General Hospital · Boston, United StatesContact person changed (no phone or email listed)
    + 4 other changes: verification date, conditions, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06239194
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Jun 12, 2024
Primary completion
Aug 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Email recommended
Contact
info@modextx.com
(857) 233-9936

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion